172 related articles for article (PubMed ID: 19771476)
1. Purified capsular polysaccharide of Neisseria meningitidis serogroup A as immune potentiator for antibody production.
Menéndez T; Carmenate T; Cruz-Leal Y; Coizeau E; Caballero E; Bello D; Guirola M; Alvarez A; Guillén G
Curr Microbiol; 2010 Feb; 60(2):79-84. PubMed ID: 19771476
[TBL] [Abstract][Full Text] [Related]
2. Development of meningococcal polysaccharide conjugate vaccine that can elicit long-lasting and strong cellular immune response with hepatitis B core antigen virus-like particles as a novel carrier protein.
Xu L; Li Z; Su Z; Yang Y; Ma G; Yu R; Zhang S
Vaccine; 2019 Feb; 37(7):956-964. PubMed ID: 30655174
[TBL] [Abstract][Full Text] [Related]
3. Combined meningococcal serogroup A and W135 outer-membrane vesicles activate cell-mediated immunity and long-term memory responses against non-covalent capsular polysaccharide A.
Romeu B; Lastre M; García L; Cedré B; Mandariote A; Fariñas M; Oliva R; Rosenqvist E; Pérez O
Immunol Res; 2014 Jan; 58(1):75-85. PubMed ID: 23660844
[TBL] [Abstract][Full Text] [Related]
4. Disparity in functional activity between serum anticapsular antibodies induced in adults by immunization with an investigational group A and C Neisseria meningitidis-diphtheria toxoid conjugate vaccine and by a polysaccharide vaccine.
Harris SL; Finn A; Granoff DM
Infect Immun; 2003 Jun; 71(6):3402-8. PubMed ID: 12761124
[TBL] [Abstract][Full Text] [Related]
5. Conjugation of β-glucan markedly increase the immunogencity of meningococcal group Y polysaccharide conjugate vaccine.
Qiao W; Ji S; Zhao Y; Hu T
Vaccine; 2015 Apr; 33(17):2066-72. PubMed ID: 25728319
[TBL] [Abstract][Full Text] [Related]
6. Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis.
Norheim G; Aase A; Caugant DA; Høiby EA; Fritzsønn E; Tangen T; Kristiansen P; Heggelund U; Rosenqvist E
Vaccine; 2005 May; 23(29):3762-74. PubMed ID: 15893613
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
[TBL] [Abstract][Full Text] [Related]
8. Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines.
Tunheim G; Arnemo M; Næss LM; Fjeldheim ÅK; Nome L; Bolstad K; Aase A; Mandiarote A; González H; González D; García L; Cardoso D; Norheim G; Rosenqvist E
Vaccine; 2013 Dec; 31(51):6097-106. PubMed ID: 24120679
[TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of phage-displayed peptide mimetics of Neisseria meningitidis serogroup B capsular polysaccharide.
Menéndez T; Santiago-Vispo NF; Cruz-Leal Y; Coizeau E; Garay H; Reyes O; Batista Y; Cobas K; Carmenate T; Chinea G; Guillén G
Int J Med Microbiol; 2011 Jan; 301(1):16-25. PubMed ID: 20708963
[TBL] [Abstract][Full Text] [Related]
10. Four monoclonal antibodies against capsular polysaccharides of Neisseria meningitidis serogroups A, C, Y and W135: its application in identity tests.
Reyes F; Amin N; Otero O; Aguilar A; Cuello M; Valdés Y; García LG; Cardoso D; Camacho F
Biologicals; 2013 Jul; 41(4):275-8. PubMed ID: 23791517
[TBL] [Abstract][Full Text] [Related]
11. Conjugates of group A and W135 capsular polysaccharides of neisseria meningitidis bound to recombinant Staphylococcus aureus enterotoxin C1: preparation, physicochemical characterization, and immunological properties in mice.
Jin Z; Bohach GA; Shiloach J; Norris SE; Freedberg DI; Deobald C; Coxon B; Robbins JB; Schneerson R
Infect Immun; 2005 Dec; 73(12):7887-93. PubMed ID: 16299279
[TBL] [Abstract][Full Text] [Related]
12. A glycoconjugate vaccine for Neisseria meningitidis induces antibodies in human infants that afford protection against meningococcal bacteremia in a neonate rat challenge model.
Mountzouros KT; Belanger KA; Howell AP; Bixler GS; Madore DV
Infect Immun; 2002 Dec; 70(12):6576-82. PubMed ID: 12438327
[TBL] [Abstract][Full Text] [Related]
13. Bordetella pertussis fimbriae are effective carrier proteins in Neisseria meningitidis serogroup C conjugate vaccines.
Reddin KM; Crowley-Luke A; Clark SO; Vincent PJ; Gorringe AR; Hudson MJ; Robinson A
FEMS Immunol Med Microbiol; 2001 Aug; 31(2):153-62. PubMed ID: 11549423
[TBL] [Abstract][Full Text] [Related]
14. Investigating the immunodominance of carbohydrate antigens in a bivalent unimolecular glycoconjugate vaccine against serogroup A and C meningococcal disease.
Adamo R; Nilo A; Harfouche C; Brogioni B; Pecetta S; Brogioni G; Balducci E; Pinto V; Filippini S; Mori E; Tontini M; Romano MR; Costantino P; Berti F
Glycoconj J; 2014 Dec; 31(9):637-47. PubMed ID: 25256065
[TBL] [Abstract][Full Text] [Related]
15. Preclinical immunogenicity study of trivalent meningococcal AWX-OMV vaccines for the African meningitis belt.
Tunheim G; Naess LM; Acevedo R; Fjeldheim ÅK; Bolstad K; García L; Cardoso D; Aase A; Zayas C; González H; Rosenqvist E; Norheim G
Vaccine; 2014 Nov; 32(49):6631-8. PubMed ID: 25305564
[TBL] [Abstract][Full Text] [Related]
16. A stabilized glycomimetic conjugate vaccine inducing protective antibodies against Neisseria meningitidis serogroup A.
Enotarpi J; Tontini M; Balocchi C; van der Es D; Auberger L; Balducci E; Carboni F; Proietti D; Casini D; Filippov DV; Overkleeft HS; van der Marel GA; Colombo C; Romano MR; Berti F; Costantino P; Codeé JDC; Lay L; Adamo R
Nat Commun; 2020 Sep; 11(1):4434. PubMed ID: 32895393
[TBL] [Abstract][Full Text] [Related]
17. Structure of a protective epitope reveals the importance of acetylation of
Henriques P; Dello Iacono L; Gimeno A; Biolchi A; Romano MR; Arda A; Bernardes GJL; Jimenez-Barbero J; Berti F; Rappuoli R; Adamo R
Proc Natl Acad Sci U S A; 2020 Nov; 117(47):29795-29802. PubMed ID: 33158970
[TBL] [Abstract][Full Text] [Related]
18. Prior meningococcal A/C polysaccharide vaccine does not reduce immune responses to conjugate vaccine in young adults.
Lakshman R; Burkinshaw R; Choo S; Finn A
Vaccine; 2002 Nov; 20(31-32):3778-82. PubMed ID: 12399209
[TBL] [Abstract][Full Text] [Related]
19. The Neisseria meningitidis macrophage infectivity potentiator protein induces cross-strain serum bactericidal activity and is a potential serogroup B vaccine candidate.
Hung MC; Salim O; Williams JN; Heckels JE; Christodoulides M
Infect Immun; 2011 Sep; 79(9):3784-91. PubMed ID: 21708989
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant can improve protection induced by OMV vaccine against Neisseria meningitidis serogroups B/C in neonatal mice.
Fukasawa LO; Dias WO; Schenkman RP; Raw I; Tanizaki MM
FEMS Immunol Med Microbiol; 2004 Jul; 41(3):205-10. PubMed ID: 15196569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
